Phase 0 clinical studies in oncology. - Wikidata - awgldk - TriplyDB

Phase 0 clinical studies in oncology.

Phase 0 clinical studies in oncology.

http://www.wikidata.org/entity/Q37358487

about

S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis Advances in cancer therapeutics Dose-toxicity models in oncology.Experimental Therapeutic Trial Design for Pediatric Brain Tumors.

P2860

Q34680962-09471C85-3986-453D-B5A5-AD5DE4A8A633 Q37069339-8F66341F-247F-43D5-B731-C007353498FC Q37829437-4C87F3AE-963F-4398-8B6D-13C52B4BF54E Q38583655-45601D48-6E0A-496B-BFE8-DFDD3009CF38

P2860

Phase 0 clinical studies in oncology.

http://www.wikidata.org/entity/Q37358487

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase 0 clinical studies in oncology.

@en

Phase 0 clinical studies in oncology.

@nl

type

label

Phase 0 clinical studies in oncology.

@en

Phase 0 clinical studies in oncology.

@nl

prefLabel

Phase 0 clinical studies in oncology.

@en

Phase 0 clinical studies in oncology.

@nl

P1433

Q37358487-52BDD341-A80E-43BE-9CF7-AF5B3EE2E68D

P1476

Q37358487-BC48E447-D672-45BD-A1EF-5960F3B9CD23

P2093

Q37358487-B501A47A-C052-4339-B213-222C2255EF79

P2860

Q37358487-211D141F-1756-482B-B0FF-2CD59A219EF6

Q37358487-68DC0E30-65C3-4342-8A98-1FA6803AB5D8

Q37358487-7823D416-366A-4022-844A-0F39898A9F35

Q37358487-79D1821C-5E46-4981-8642-9D7DBB4758E6

Q37358487-86E0BFEC-EAE4-405E-BF73-85567B114B37

Q37358487-B9AED5FA-FE07-4F35-ADAF-48D72ADF0903

Q37358487-C5CF2DB7-9ED1-4642-B8C9-492579A9314A

Q37358487-DCB3DC71-AB48-45A3-A1D4-5A08BA821D3B

Q37358487-F01673C4-C7B8-41C4-8E62-192B3B3903EA

P304

Q37358487-F22AAA89-6C0A-47DB-9445-1CFAC913B1C0

P31

Q37358487-C7A68189-BA3E-4635-A358-73D16A2F318A

P356

Q37358487-C06C23D0-4E81-47AF-9101-423AC289AC97

P407

Q37358487-EFCB3DF6-6910-4216-84C2-35372234114A

P433

Q37358487-C89FB203-9245-407E-B82F-5F58B47D9934

P478

Q37358487-8EB3E6E6-C1BD-4FC5-89BF-0F15F0FD6138

P577

Q37358487-7D9BD219-CBA8-443B-91A4-91B401896AA4

P698

Q37358487-E733D20F-9010-49FE-B13B-E8A71EF1C36A

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Phase 0 clinical studies in oncology.

@en

P2093

J M Collins

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical biomarkers in drug discovery and development.

Designing phase 0 cancer clinical trials.

Innovative early development regulatory approaches: expIND, expCTA, microdosing.

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

Phase 0 trials: an industry perspective.

Pharmacologically guided phase I clinical trials based upon preclinical drug development.

Patient perspectives on phase 0 clinical trials.

Compressing drug development timelines in oncology using phase '0' trials.

Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.

P304

204-207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2008.246

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19109589

http://www.w3.org/2001/XMLSchema#string